Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 13, No 1 (2017) CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION Abstract  similar documents
S. V. Nedogoda, I. N. Barykina, A. S. Salasiuk, V. O. Smirnova
"... with "decision tree" modeling is performed. The costs of regimens using rivaroxaban and apixaban were calculated ..."
 
Vol 13, No 5 (2017) DRUG INTERACTIONS OF NEW ORAL ANTICOAGULANTS: INSIDE AND OUTSIDE TABLE CELLS Abstract  similar documents
S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov
"... The opinion is expressed in some  domestic publications that  rivaroxaban has  the  most ..."
 
Vol 9, No 3 (2013) ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT Abstract  similar documents
E. L. Dolgova, I. M. Sokolov, Yu. G. Shvarts
"... неклапанной фибрилляции предсердий, об особенностях антикоагулянтной терапии при данной патологии и трудностях ..."
 
Vol 11, No 3 (2015) ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION Abstract  similar documents
A. V. Rudakova
"... and rivaroxaban). Aim. To assess the influence of apixaban use on the budget as an alternative to warfarin ..."
 
Vol 11, No 1 (2015) PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION Abstract  similar documents
A. V. Rudakova
"... (warfarin), antiplatelet therapy (acetylsalicylic acid) and novel oral anticoagulants such as apixaban ..."
 
Vol 13, No 6 (2017) PREDICTORS OF THE RISK OF HEMORRHAGIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION RECEIVING LONGTERM THERAPY WITH DIRECT ORAL ANTICOAGULANTS Abstract  similar documents
A. А. Sokolova, A. V. Zhilenko, I. L. Tsarev,, D. A. Napalkov, V. V. Fomin
"... – rivaroxaban and apixaban) were included into the cohort study in parallel groups. In addition to evaluate ..."
 
Vol 12, No 4 (2016) Clinical significance of new oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation: not all dreams come true Abstract  similar documents
Yu. A. Bunin, S. V. Miklishanskaya
"... составляет 1-2%. Неклапанная ФП увеличивает риск развития ишемического инсульта в 5-7 раз. Более 50 ..."
 
Vol 13, No 1 (2017) DATA OF CLINICAL PRACTICE AS A TOOL FOR CHOICE OF DIRECT ORAL ANTICOAGULANT Abstract  similar documents
D. А. Napalkov, A. A. Sokolova, V. V. Fomin
"... anticoagulants, apixaban is associated with the best adherence to treatment and lowest bleeding incidence ..."
 
Vol 15, No 2 (2019) Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology Abstract  similar documents
S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov, G. Yu. Trufanova
"... for two RCTs with rivaroxaban - EINSTEIN-DVT and EINSTEIN-PE) contained data on the participation of frail ..."
 
Vol 12, No 5 (2016) Features of Modern Anticoagulant Therapy in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease Abstract  similar documents
I. S. Daabul, A. A. Sokolova, D. A. Napalkov
"... предсердий неклапанной этиологии и ХБП. Анализируется возможность максимально безопасного применения ..."
 
Vol 15, No 5 (2019) Rivaroxaban-Associated Hepatotoxicity: a Clinical Case and Literature Review Abstract  similar documents
B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov
"... . Direct oral anticoagulants, particularly rivaroxaban, are widely used for deep vein thrombosis/pulmonary ..."
 
Vol 14, No 2 (2018) NEW DIRECT ORAL ANTICOAGULANTS FOR TREATMENT OF PATIENTS WITH ATRIAL FIBRILLATION IN REAL-WORLD SETTING Abstract  similar documents
Zh. D. Kobalava, S. V. Villevalde, A. A. Shavarov
"... given rivaroxaban appeared to have higher rate of hemorrhagic events. High adherence to apixaban ..."
 
Vol 13, No 3 (2017) PHARMACOGENETIC ASPECTS OF NEW ORAL ANTICOAGULANTS APPLICATION Abstract  similar documents
A. V. Kryukov, D. A. Sychev, O. V. Tereshchenko
"... of genotype on rivaroxaban pharmacokinetics in the study involving the carriers of ABCB1 gene rs2032582 and rs ..."
 
Vol 7, No 5 (2011) ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: RECENT APPROACHES AND NEAR PERSPECTIVES Abstract  similar documents
Ya. P. Dovgalevskiy, L. E. Kuvshinova, I. V. Graifer, N. V. Furman, P. Ya. Dovgalevskiy
 
Vol 9, No 4 (2013) COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS Abstract  similar documents
V. A. Sulimov, D. A. Napalkov, A. A. Sokolova
"... Indirect comparisons of new oral anticoagulants are performed with focus on their safety. Apixaban ..."
 
Vol 10, No 4 (2014) NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY Abstract  similar documents
D. A. Napalkov, A. A. Sokolova
"... dabigatran, rivaroxaban and apixaban) is presented from the standpoint of safety. The safety profile ..."
 
Vol 10, No 3 (2014) COST-EFFECTIVENESS OF APIXABAN AS COMPARED WITH WARFARIN AND ACETYLSALICYLIC ACID IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE RUSSIAN FEDERATION Abstract  similar documents
A. V. Rudakova, V. A. Parfenov
"... anticoagulants such as apixaban, rivaroxaban and dabigatran. Administration of vitamin K antagonists (VKA ..."
 
Vol 12, No 2 (2016) THE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION IN CLINICAL PRACTICE Abstract  similar documents
S. V. Moiseev
"... New oral anticoagulants that inhibit factor Xa (rivaroxaban, apixaban, edoksaban) or thrombin ..."
 
Vol 9, No 2 (2013) ERA OF NEW ANTICOAGULANTS IN THE TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION: PROSPECTS AND CHALLENGES Abstract  similar documents
Z. M. Safiullina, S. V. Shalaev
"... inhibitors of coagulation factor Xa (rivaroxaban, apixaban), in the treatment of nonvalvular atrial ..."
 
Vol 14, No 4 (2018) Hepatotoxicity of New Oral Anticoagulants Abstract  similar documents
A. R. Kasimova, A. V. Philippova (Guryanova), A. S. Kolbin
 
Vol 15, No 6 (2019) Safety of Non-Vitamin K Oral Anticoagulants in Elderly Patients with Atrial Fibrillation Abstract  similar documents
M. A. Gabitova, P. M. Krupenin, A. A. Sokolova, D. A. Napalkov, V. V. Fomin
"... of age with confirmed AF, receiving dabigatran in a reduced dosage, apixaban or rivaroxaban in full ..."
 
Vol 14, No 5 (2018) Bayer registered a new indication for rivaroxaban for use in patients with coronary heart disease or peripheral artery disease in the European Union and USA Abstract  similar documents
Bayer Company Press Release
"... антикоагулянта ривароксабана в дозе 2,5 мг 2 р/д в сочетании с 75-100 мг ацетилсалициловой кислоты один раз в ..."
 
Vol 12, No 5 (2016) The Anticoagulation in Patients with Atrial Fibrillation: Rivaroxaban and Warfarin Abstract  similar documents
I. Yu. Koroleva, I. V. Kolesnichenko, V. P. Nosov, M. V. Zlobin, D. I. Abelevich
"... Aim. To study the effect of rivaroxaban compared with warfarin on the incidence of cardioembolic ..."
 
Vol 14, No 3 (2018) THROMBOSIS OF LEFT ATRIAL APPENDAGE DURING THERAPY WITH DIRECT ORAL ANTICOAGULANT. CLINICAL CASE Abstract  similar documents
I. S. Daaboul, S. Yu. Koroleva, A. A. Kudrjavtseva, A. A. Sokolova, D. A. Napalkov, V. V. Fomin
"... long-term anticoagulant therapy with apixaban in a full dose (5 mg b.i.d.), and the patient ..."
 
Online First Clinical Significance of Thrombin Blockade with Low Doses (2.5 mg) of Rivaroxaban in Ischemic Heart Disease Patients Abstract  similar documents
A. B. Sumarokov, L. I. Buryachkovskaya, Y. V. Docenko, M. S. Kurochkin, N. V. Lomakin
"... of antiplatelet therapy. The combination of rivaroxaban in a dose of 2.5 mg and standard double antiplatelet ..."
 
Vol 12, No 5 (2016) Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation Abstract  similar documents
N. A. Novikova, A. N. Volovchenko
"... showed the efficacy and safety of rivaroxaban and apixaban in preparation and performance of electrical ..."
 
Vol 12, No 4 (2016) Application of rivaroxaban in clinical practice: results of a prospective observational study XANTUS in patients with atrial fibrillation Abstract  similar documents
S. G. Kanorskii
"... In XANTUS study the safety and efficacy of factor Xa inhibitor rivaroxaban were evaluated ..."
 
Vol 14, No 4 (2018) Possibilities of Using Rivaroxaban in Elderly Patients with Atrial Fibrillation: Data from Randomized Studies and Real Clinical Practice Abstract  similar documents
N. M. Vorobyeva, O. N. kacheva
"... The possibility of rivaroxaban using in elderly patients with non-valvular atrial fibrillation ..."
 
Vol 15, No 4 (2019) According to the AUGUSTUS Trial Apixaban (Eliquis ® ) was Found to Be Safer than Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation with Acute Coronary Syndrome and/or Percutaneous Coronary Intervention Abstract  similar documents
Company Pfizer
"... неклапанной фибрилляции предсердий и острым коронарным синдромом и/или чрескожным коронарным вмешательством ..."
 
Vol 10, No 3 (2014) PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN ATRIAL FIBRILLATION - RAT POISON OR NEW ORAL ANTICOAGULANTS: DO WE HAVE A CHOICE, AND SHOULD WE BE AFRAID TO MAKE IT? FIRST CLINICAL EXPERIENCE WITH RIVAROXABAN IN NIZHNY NOVGOROD Abstract  similar documents
L. Y. Koroleva, I. V. Kolesnichenko, V. P. Nosov, I. I. Gritsenko, E. S. Timoschenko
"... attractive, is rivaroxaban. ..."
 
Vol 12, No 3 (2016) THE PHARMACOKINETICS OF APIXABAN IN PATIENTS WITH CARDIOEMBOLIC STROKE IN ACUTE PHASE Abstract  PDF (Eng)  similar documents
A. V. Kryukov, D. A. Sychev, D. A. Andreev, A. V. Ryabova, N. P. Denisenko, M. A. Loskutnikov, O. I. Vinogradov, M. A. Domashenko
"... Aim. To study pharmacokinetics of apixaban in patients with atrial fibrillation and cardioembolic ..."
 
Vol 11, No 5 (2015) Practical aspects of apixaban use in clinical practice: continuing the theme Abstract  similar documents
S. N. Bel'diev
"... Currently there are no generally accepted guidelines for the use of apixaban together with CYP3A4 ..."
 
Vol 10, No 3 (2014) EUROPEAN MEDICINES AGENCY APPROVED APIXABAN USE IN CARDIOVERSION Abstract  similar documents
"... European Medicines Agency approved apixaban use in cardioversion. ..."
 
Vol 8, No 3 (2012) RIVAROXABAN IN THE PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH ATRIAL FIBRILLATION Abstract  similar documents
M. Yu. Gilyarov
"... . The alternative antithrombotic agents, including rivaroxaban presented along with the traditional drugs (acetyl ..."
 
Vol 8, No 4 (2012) THE RISK OF BLEEDINGS IN PATIENTS WITH ATRIAL FIBRILLATION DURING ANTICOAGULANT THERAPY Abstract  similar documents
M. Yu. Gilyarov
"... . Along with traditional drugs (acetylsalicylic acid, warfarin) rivaroxaban is specially considered ..."
 
Vol 11, No 2 (2015) PRACTICAL ASPECTS OF APIXABAN USE IN CLINICAL PRACTICE: VIEW POINT OF CLINICAL PHARMACOLOGIST Abstract  similar documents
D. A. Sychev, I. I. Sinitsina, G. Yu. Zakharova, M. I. Savel'eva, A. V. Ryabova, A. V. Kryukov, A. Yu. Yurovskii
"... Apixaban is a "new" oral anticoagulant, direct Xa factor inhibitor with a good evidence base ..."
 
Vol 11, No 6 (2015) Clinical and economic analysis of the use of apixaban for the treatment of venous thromboembolic events Abstract  similar documents
O. V. Shatalova
"... Aim. Pharmacoeconomic analysis of apixaban use compared to conventional therapy in patients ..."
 
Vol 15, No 4 (2019) Elderly Patients with Atrial Fibrillation: Focus on Comorbidity and Safety of Anticoagulant Therapy Abstract  similar documents
D. A. Napalkov, A. A. Sokolova
"... results demonstrate a favorable efficiency and safety profile of rivaroxaban in comparison with warfarin ..."
 
Vol 13, No 5 (2017) WARFARIN AND ITS IMPORTANCE IN THE ERA OF NEW ORAL ANTICOAGULANTS. ISSUES OF MONITORING THE EFFECTIVENESS AND SAFETY OF TREATMENT Abstract  similar documents
S. Yu. Martsevich, Y. V. Lukina
"...   of new OAC (NOAC) also appeared. In Russia, dabigatran, rivaroxaban and apixaban have been registered ..."
 
Vol 14, No 5 (2018) Anticoagulant Therapy in Difficult Patients with Atrial Fibrillation: When the Risks of Embolism and Bleeding Are Comparable Abstract  similar documents
D. A. Napalkov, A. A. Sokolova, M. A. Gabitova, L. N. Uddin
"... ) on rivaroxaban therapy are presented. Good efficacy and  safety  of full and  reduced doses  of rivaroxaban were ..."
 
Vol 12, No 1 (2016) Interaction of rivaroxaban with amiodarone, verapamil and diltiazem in patients with atrial fibrillation: terra incognita Abstract  similar documents
S. N. Bel'diev
"... Currently there are no generally accepted guidelines for the use of rivaroxaban together ..."
 
Vol 14, No 3 (2018) APPROACHES TO THE CHOICE OF ANTICOAGULANT THERAPY IN THE TREATMENT OF PATIENTS WITH COMBINATION OF ATRIAL FIBRILLATION WITH CORONARY HEART DISEASE OR PERIPHERAL ATHEROSCLEROSIS: POTENTIAL OF APIXABAN Abstract  similar documents
O. D. Ostroumova, A. I. Kochetkov, I. Yu. Orlova, E. A. Smolyarchuk, J. S. Pavlova
"... of efficacy and safety of apixaban in patients with AF, depending on the presence of CHD, PAD, concomitant use ..."
 
Vol 12, No 3 (2016) THE ADVANCED TACTICS OF THE MANAGEMENT OF PATIENTS WITH VENOUS THROMBOEMBOLISM: THE ROLE OF RIVAROXABAN AT VARIOUS STAGES OF TREATMENT Abstract  PDF (Eng)  similar documents
S. R. Gilyarevskiy
"... the validity of monotherapy tactics with rivaroxaban in patients with VTE. The results of this study ..."
 
Vol 14, No 6 (2018) The Results of Rivaroxaban Studies COMMANDER HF and MARINER Were Published. Bayer Company Press Release . Abstract  PDF (Eng)  similar documents
artilce Editorial
 
Vol 15, No 6 (2019) Adherence to Treatment with New Oral Anticoagulants in Atrial Fibrillation Patients in Real Clinical Practice (Results of the ANTEY Study) Abstract  similar documents
S. Yu. Martsevich, Yu. V. Lukina, N. P. Kutishenko, S. N. Tolpygina, V. P. Voronina, N. A. Dmitrieva, O. V. Lerman, N. A. Komkova
"... recommended the use of rivaroxaban; 47 (23.4%) – the use of dabigatran and 43 (21.4%) – the use of apixaban ..."
 
Vol 13, No 2 (2017) RIVAROXABAN HAS DEMONSTRATED AN ADVANTAGE OVER ACETYLSALICYLIC ACID IN PREVENTING THE RECURRENCE OF VENOUS THROMBOEMBOLIC EVENTS IN THE EINSTEIN CHOICE STUDY Abstract  similar documents
. Editorial
"... эффективность и безопасность ривароксабана в дозах 20 мг 1 р/д*, 10 мг 1 р/д и ацетилсалициловой кислоты в дозе ..."
 
Vol 15, No 4 (2019) Optimization of Pharmacotherapy with Direct Oral Anticoagulants: the Need to Choose the Right Dosage Regimen Abstract  similar documents
A. I. Kochetkov, O. D. Ostroumova
"... profile and multimorbidity. In these terms, apixaban stands high among the DOAC class, and its high ..."
 
Vol 12, No 2 (2016) ATRIAL FIBRILLATION AND ISCHEMIC HEART DISEASE: HOW TO COMBINE ANTIPLATELET AND ANTICOAGULANT THERAPY, DEPENDING ON THE CLINICAL SITUATION? Abstract  similar documents
D. A. Napalkov, A. A. Sokolova, A. V. Rodionov
"... and safety of apixaban with these of warfarin in patients with atrial fibrillation and a history of ischemic ..."
 
Vol 10, No 2 (2014) RIVAROXABAN IN PATIENTS STABILIZED AFTER A ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION. RESULTS FROM THE ATLAS ACS-2–TIMI-51 TRIAL Abstract  similar documents
J. L. Mega, E. Braunwald, S. A. Murphy, A. N. Plotnikov, P. Burton, R. G. Kiss, A. Parkhomenko, M. Tendera, P. Widimsky, C. M. Gibson
"... Цель. Представлен анализ лечения ривароксабаном в заранее определенной подгруппе больных инфарктом ..."
 
Vol 11, No 5 (2015) New data of the real clinical practice confirms low incidence of major bleeding when using rivaroxaban in patients with non-valvular atrial fibrillation Abstract  similar documents
article Editorial
"... rivaroxaban in patients with non-valvular atrial fibrillation  ..."
 
Vol 13, No 5 (2017) ADHERENCE TO THE USE OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION – THE WAY TO SOLVE THE PROBLEM OF EFFICACY AND SAFETY OF TREATMENT Abstract  similar documents
S. G. Kanorskii
"... . Rivaroxaban can be given in fixed doses without routine coagulation control, and phase III studies and actual ..."
 
Vol 15, No 3 (2019) Treatment of Patients with Stable Manifestations of Atherosclerosis: New Opportunities Abstract  similar documents
article Editorial
"... of both coagulation and platelet). Experts noted that combination of rivaroxaban 2.5 mg BID ..."
 
Vol 15, No 6 (2019) New Opportunities for Improving the Prognosis of Patients with Chronic Ischemic Heart Disease Abstract  similar documents
N. B. Perepech
"... , which obtained confirmation of the positive effect of combined therapy with rivaroxaban ..."
 
Vol 13, No 5 (2017) RIVAROXABAN OF THE BAYER COMPANY SIGNIFICANTLY (BY 24%) REDUCES THE RISK OF STROKE, CARDIOVASCULAR DEATH AND MYOCARDIAL INFARCTION IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE OR PERIPHERAL ARTERIAL DISEASE Abstract  similar documents
статья Редакционная
 
Vol 15, No 5 (2019) Anticoagulant Therapy as a Tool for the Prevention of Cognitive Impairment Associated with Atrial Fibrillation Abstract  similar documents
O. D. Ostroumova, A. I. Kochetkov, S. P. Korchagina, T. M. Ostroumova, M. S. Chernyaeva, A. A. Kirichenko
"... strategy for preventing stroke associated with AF. Among the DOAC class, rivaroxaban is worth noticing ..."
 
Vol 12, No 6 (2016) NEW DATA OF EXTENSIVE RESEARCH PROGRAM AND THE RESULTS OF STUDIES IN REAL CLINICAL PRACTICE FROM DIFFERENT COUNTRIES REAFFIRMED THE HIGH EFFICACY AND A FAVORABLE SAFETY PROFILE OF RIVAROXABAN (XARELTO®) FROM THE BAYER COMPANY PRESS RELEASE OF THE BAYER COMPANY Abstract  similar documents
article editorial
 
Vol 15, No 5 (2019) Findings Released from NAXOS Analysis. Pfizer Company Press Release Abstract  similar documents
article Editorial
"... Компания Pfizer представила результаты когортного исследования NAXOS (EvaluatioN of ApiXaban in ..."
 
Vol 11, No 2 (2015) ANTICOAGULANT THERAPY IN EVERYDAY CLINICAL PRACTICE: DATA OF THE RETROSPECTIVE CROSS-SECTIONAL STUDY Abstract  PDF (Eng)  similar documents
V. A. Sulimov, D. A. Napalkov, A. A. Sokolova, A. V. Jilenko, O. S. Anikina
"... % of the patients received novel oral anticoagulants (dabigatran – 14%, rivaroxaban – 2%). Bleeding was fixed in 4 ..."
 
Vol 11, No 5 (2015) Cost-effectiveness of new oral anticoagulants in the treatment and secondary prevention of venous thromboembolism Abstract  similar documents
A. V. Rudakova
"... Aim. To assess the cost-effectiveness of apixaban in the treatment and secondary prevention ..."
 
Vol 11, No 3 (2015) PHARMACOECONOMIC ASPECTS OF THE PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS AFTER LARGE JOINTS REPLACEMENT Abstract  similar documents
A. V. Rudakova
"... average prices of public bidding for the purchase of drugs (enoxaparin, dabigatran and apixaban) during ..."
 
Vol 9, No 6 (2013) THE ROLE OF P-GLYCOPROTEIN IN RATIONAL PHARMACOTHERAPY IN CARDIOLOGY Abstract  similar documents
A. V. Shulkin, E. N. Yakusheva, N. M. Popova
"... , prasugrel) and anticoagulants (dabigatran etexilate, rivaroxaban, edoxaban) is not feasible in routine ..."
 
Vol 14, No 6 (2018) Anticoagulant Therapy in “Fragile” Elderly Patients: Current State of the Problem Abstract  PDF (Eng)  similar documents
N. M. Vorobyeva, O. N. Tkacheva
"... showed that only therapy with rivaroxaban (out of three direct oral anticoagulants) compared ..."
 
Vol 6, No 4 (2010) ANTITHROMBOTIC THERAPY IN NONVALVULAR ATRIAL FIBRILLATION: PROBLEMS AND PROSPECTS Abstract  similar documents
A. Y. Rychkov, N. Y. Khor'kova, A. A. Bliznyakov
"... осложнений, ассоциированных с неклапанной фибрилляцией предсердий, в частности ишемического инсульта. В ..."
 
Vol 12, No 4 (2016) New data from clinical practice again confirmed the high efficacy and a favorable safety profile of the drug Xarelto® in patients with atrial fibrillation (Press release of the company Bayer) Abstract  similar documents
Article Editorial
"... внутричерепных кровотечений на фоне терапии препаратом Ксарелто® (ривароксабан) по сравнению с варфарином у ..."
 
Vol 10, No 2 (2014) SECONDARY PREVENTION OF STROKE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: THE CLINICIANS’ VIEWPOINT Abstract  similar documents
E. A. Drozdova
"... . Рассматриваются актуальные проблемы ведения больных с инсультами, возникшими на фоне неклапанной фибрилляции ..."
 
Vol 10, No 4 (2014) MODERN APPROACHES TO ANTICOAGULANT THERAPY DURING CATHETER ABLATION TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION Abstract  similar documents
E. A. Belikov, K. V. Davtyan, O. N. Tkacheva
 
Vol 7, No 6 (2011) DABIGATRAN ETEXILATE FOR PREVENTION OF CARDIOEMBOLIC COMPLICATIONS IN NONVALVULAR ATRIAL FIBRILLATION: HOW TO DO THE INTERVENTION MORE EFFECTIVE AND SAFER Abstract  similar documents
I. S. Yavelov
"... неклапанной фибрилляции предсердий. С учетом результатов крупного рандомизированного клинического исследования ..."
 
Vol 14, No 2 (2018) New Possibilities of Antithrombotic Therapy of Patients with Peripheral and Widespread Atherosclerotic Lesion Abstract  similar documents
A. L. Komarov, Е. S. Novikova, E. V. Guskova, Е. B. Yarovaya, A. N. Samko, E. Р. Panchenko
"... , that was demonstrated in a recently published study COMPASS. Treatment with rivaroxaban small doses in addition ..."
 
Vol 14, No 6 (2018) Antithrombotic Therapy in Patients with Atrial Fibrillation after Myocardial Infarction: Clinical Guidelines and Actual Practice Abstract  PDF (Eng)  similar documents
K. G. Pereverzeva, S. S. Yakushin, A. E. Pripadcheva, N. P. Agaltsova
"... was prescribed in 11 (64.7%) cases and rivaroxaban – in 6 (35.3%). Conclusion. In real clinical practice ..."
 
Vol 8, No 1 (2012) PHARMACOECONOMIC EVALUATION OF DABIGATRAN VS WARFARIN IN CARDIOVASCULAR EVENTS PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION Abstract  similar documents
Yu. B. Belousov, V. Yu. Mareev, I. S. Yavelov, D. Yu. Belousov
 
Vol 8, No 6 (2012) HOW TO USE DABIGATRAN IN PATIENTS WITH ATRIAL FIBRILLATION Abstract  similar documents
S. V. Moiseev
"... у 18000 пациентов с неклапанной фибрилляцией предсердий (ФП) дабигатран в дозе 150 мг два раза в ..."
 
Vol 9, No 4 (2013) COMPARISON OF DIRECT COSTS OF DABIGATRAN AND WARFARIN THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION DURING PREPARATION FOR ELECTIVE CARDIOVERSION IN THE REAL CLINICAL PRACTICE Abstract  similar documents
L. E. Kuvshinova, N. V. Furman, P. V. Dolotovskaya, Ya. P. Dovgalevsky
"... к кардиологу при подготовке к КВ). Включено 62 пациента с персистирующей неклапанной ФП ..."
 
Vol 15, No 1 (2019) Comparative Analysis of Antithrombotic Therapy in In-Patients with Atrial Fibrillation Abstract  similar documents
V. I. Petrov, O. V. Shatalova, A. S. Gerasimenko, V. S. Gorbatenko
"... предсердий (ФП) неклапанной этиологии, госпитализированных в кардиологическое отделение многопрофильного ..."
 
Vol 4, No 3 (2008) COMPARATIVE EFFICACY OF ACE INHIBITORS (RAMIPRIL VS ENALAPRIL) IN TREATMENT OF CHRONIC HEART FAILURE IN WOMEN Abstract  similar documents
S. N. Tereshchenko, I. V. Zhirov, E. V. Malichenko, E. E. Kazantseva
"... неклапанной этиологии. Пациентки рандомизированы в группы приема рамиприла и эналаприла в дополнение к ..."
 
Vol 12, No 3 (2016) THE PREDICTION OF ATRIAL FIBRILLATION RECURRENCE AT VARIOUS METHODS OF SINUS RHYTHM RECOVERY Abstract  PDF (Eng)  similar documents
T. Y. Gromyko, S. A. Sayganov
"... восстановления синусового ритма.  Материал и методы. Обследовано 153 пациента с неклапанной формой ФП ..."
 
Vol 8, No 5 (2012) RISK OF THROMBOEMBOLIC COMPLICATIONS AND ANTITHROMBOTIC THERAPY IN IN-PATIENTS WITH PERMANENT AND RECURRENT ATRIAL FIBRILLATION IN REAL CLINICAL PRACTICE Abstract  similar documents
I. V. Grajfer, L. E. Kuvshinova, P. V. Dolotovskaya, O. V. Reshet'ko, N. V. Furman
"... много- профильных стационаров на протяжении года по поводу неклапанной ФП. Оценивали риск ..."
 
Vol 15, No 5 (2019) Left Atrial Phasic Function in Patients with Hypertension and Recurrent Atrial Fibrillation: Gender Differences of the Relationship with Diastolic Dysfunction and Central Aortic Pressure Abstract  similar documents
E. V. Kokhan, E. M. Ozova, V. A. Romanova, G. K. Kiyakbaev, Zh. D. Kobalava
"... пациентов – 30 мужчин и 37 женщин с неклапанной рецидивирующей ФП, АГ и гипертрофией ЛЖ. При эхокардиографии ..."
 
1 - 77 of 77 Items

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)